Compare Moderna, Inc. (MRNA) vs Synopsys, Inc. (SNPS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Moderna, Inc. vs Synopsys, Inc. — how do they compare? Moderna, Inc. trades at $59.73 (market cap $23.60B), while Synopsys, Inc. trades at $390 (market cap $72.47B). The key difference: Synopsys, Inc. is far larger — about 3.1× Moderna, Inc.'s market cap, and Moderna, Inc. is trading nearer its 52-week high, Synopsys, Inc. nearer its low. Which is the better fit depends on your goals.
| MRNA | SNPS | |
|---|---|---|
Market Cap | $23.60B | $72.47B |
Sector | Health | Technology |
52-Week High | $81.80 | $645.59 |
52-Week Low | $22.36 | $378.46 |
Enterprise Value | $19.70B | $80.82B |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Moderna, Inc.
Moderna, Inc. operates as a clinical stage biotechnology company. The Company focuses on the discovery and development of messenger RNA (mRNA) therapeutics and vaccines. Moderna develops mRNA medicines for infectious, immuno-oncology, and cardiovascular diseases.
Read more on MRNA →About Synopsys, Inc.
Synopsys is a provider of electronic design automation software, intellectual property, and software integrity products. EDA software automates the chip design process, enhancing design accuracy, productivity, and complexity in a full-flow end-to-end solution. The firm's growing SI business allows customers to continuously manage and test the code base for security and quality. Synopsys' comprehensive portfolio is benefiting from a mutual convergence of semiconductor companies moving up-stack toward systems-like companies, and systems companies moving down-stack toward in-house chip design. The resulting expansion in EDA customers alongside secular digitalization of various end markets benefits EDA vendors like Synopsys.
Read more on SNPS →
